Changing the Treatment Paradigm in Cancer and Fibrotic Disease

learn more >

NEWS

December, 2015. "BLR Bio, as an invited company, presented their pipeline along with GlaxoSmithKline, Abbvie and Alexion, at the 47th Advance Course on Nephrology, in Milan Italy. In a program entitled: What do nephrologists want for their patients in the future, and what can pharmaceutical companies provide? Approximately one thousand nephrologists were able to respond to the newest developments for future treatment and expressed their opinions."

December, 2015. "BLR Bio, CEO Dr. Bruce Riser, along with along with co-authors at Department of Medicine, University of Texas Health Science Center, San Antonio and Department of Pathology, The University of Michigan Medical School, Ann Arbor, published a review article in the Journal of Cell Communication and Signaling entitled, ′Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer.′"

September, 2015. "BLR Bio has completed a licensing agreement with Rosalind Franklin University of Medicine and Science for a broad set of world-wide intellectual property invented by Dr. Riser, and based on discoveries in the cancer and fibrosis fields."

November, 2014. "BLR Bio published a proof of principal study, our first chronic treatment in a “best” animal model of human kidney disease as a complication of diabetes and obesity. The study, entitled "Treatment with the matricellular protein CCN3 (nov) blocks and/or reverses fibrosis development in obesity with diabetic nephropathy", appeared in the the top medical research publication, The American Journal of Pathology, and was a featured original study, also highlighted on the Journal’s Face page. It demonstrated that a three times per week administration of BLR 101, was able to totally block and even rescue from established fibrosis. This study serves to lead the way to subsequent development of this and our highly specific peptide mimetics to begin human clinical trials. Dr. Riser is the senior author, with teams from Rosalind Franklin University of Medicine and Science, The University of Texas Health Science Center, and Jackson Laboratories."

August, 2014. "BLR Bio is joining the Kidney Research United Kingdom foundation in supporting a collaborative study entitled The CCN3/CCN2 axis in human tubule epithelial cells and its implication for tubulointerstitial fibrosis. The PI is Dr. Mark Dockrell of the South West Thames Institute for Renal Research, London. Dr. Dockrell and Dr. Riser (BLR Bio CEO), have recently published abstracts of the preliminary findings at several medical research conferences in Europe."

August, 2014. "BLR Bio is supporting and collaborating in a study recently funded by the Canadian Institutes of Health Research entitled CCN2 action in fibrosis: Cellular and molecular mechanisms. The principal investigator is Dr. Andrew Leask, of the School of Medicine and Density, the University of Western Ontario. The study will focus on the role of CCN proteins in progenitor cell / myofibroblast transformation and skin fibrosis, with potential applications to scleroderma."

March 25, 2014. Keystone, CO. "BLR Bio presents a positive proof of concept animal study at Keystone Symposia conference on fibrosis."

"BLR Bio, a company focused on the treatment of fibrosis and related chronic diseases will present results from a recent chronic animal efficacy study in diabetic kidney disease (nephropathy) at the Keystone Symposia, Fibrosis: From Bench to Bedside. The data presented will demonstrate an ability of BLR-101 (recombinant human CCN3) to block, and reverse, the progression of this disease, as determined by multiple measures of fibrosis and renal function."

© BLR Bio, L.L.C. | 313 54th Street, Kenosha, WI, USA, 53140 | info@BLRbio.com

Latest News

May 2016
"Dr. Bruce Riser, CEO of BLR Bio, was an invited speaker on Peptide Discovery, Preclinical and Clinical presented at the TIDES Oligonucleotide and Peptide Therapeutics Conference, at Long Beach. See selected pre-interview."

April 2016
"BLR Bio was selected as one of the top 50 emerging biotechnology companies to present at the MedCity INVEST, Health Tech Showcase in Chicago April 10-12."

see news archives »

Publications

April 2016
Balanced Regulation of the CCN Family of Matricellular Proteins: A Novel Approach to the Prevention and Treatment of Fibrosis and Cancer.
Journal of Cell Communication and Signaling 9.4 (2015): 327–339.
PMC. Web. 28 Apr. 2016.

more publications »